Shanghai Ark Biopharmaceutical Co., Ltd.

This early-stage study is the first time AK0406 is being tested in humans. It will involve 32 healthy adults to check if the drug is safe and how the body processes it. No treatment is being given for any disease—this is purely a safety check.